Related Experiment Videos
Ertapenem for treatment of extended-spectrum beta-lactamase-producing and multidrug-resistant gram-negative
David Chien Lye1, Limin Wijaya, Joey Chan
1Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore. david_lye@ttsh.com.sg
Introduction:
Imipenem and meropenem are treatment of choice for extended-spectrum betalactamase (ESBL)-positive gram-negative bacteraemia. They may select for carbapenemresistant Acinetobacter baumannii and Pseudomonas aeruginosa; ertapenem may not do so as it is inactive against these bacteria. Clinical efficacy of ertapenem in ESBL-producing gramnegative bacteraemia is limited.
Materials And Methods:
Retrospective study of patients with ESBL-positive gram-negative bacteraemia treated with ertapenem was undertaken.
Results:
Forty-seven patients with multidrug-resistant gram-negative bacteraemia (79% produced ESBL) were treated with ertapenem for a median duration of 11 days. The median age was 70 years. Septic shock occurred in 19% and mechanical ventilation was needed in 17%. Klebsiella pneumoniae comprised 53% and Escherichia coli 26%. Urinary infection accounted for 61% and hepatobiliary 15%. Favourable clinical response occurred in 96%. Attributable mortality was 4%.
Conclusion:
Ertapenem is promising in culture-guided step-down therapy of ESBL-positive gram-negative bacteraemia.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Inhibitors of Gram-positive Cell Wall Synthesis
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Development of Antibiotic Resistance